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Abstract 
Macroautophagy is a catabolic cellular process responsible for bulk degradation of proteins. 
Largely conserved from yeast to mammals, the initiating steps of autophagy and key signalling 
proteins governing the complex biological process have been initially characterised. However, 
very little is known of one critical protein kinase, ULK1, which is thought to govern the 
induction of autophagy. ULK1 is regulated by two upstream kinases, via energy sensing through 
AMPK and nutrient sensing through mTORC1. While several studies have identified ULK1 
binding partners in cells, the list of functional interactions remains limited. Further, as an 
enzyme, the targets of ULK1 and the possibility of a consensus phosphorylation motif remains 
largely unknown. Herein, using a phosphoproteomic screen and purification approaches, we 
identify new ULK1 protein interactions and ULK1-mediated phosphorylation events. A novel 
ULK1 kinase inhibitor is also initially characterised, which potently blocks ULK1 
phosphotransfer to downstream substrates and itself, and autophagosomal maturation in 
mammalian cells. Furthermore, examining a known ULK1 binding partner, FLCN, we explore 
novel molecular aspects of a rare genetic disease, Birt-Hogg-Dubé syndrome and its connection 
as a ciliopathy.  
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1. Introduction 
Macroautophagy (herein now referred to as autophagy) is an ancient catabolic, cellular process 
responsible for bulk degradation of dysfunctional proteins and organelles. First coined in 1963, 
by the Nobel Laureate Christian de Duve, autophagy is characterized by the formation of double-
membrane vesicles, called autophagosomes, and their subsequent fusion to lysosomal bodies to 
provide the cell with greater nutrient availability particularly during fasting or nutrient-deprived 
conditions. As a distinct pathway from the proteosomal turnover of ubiquitinated, unstable 
proteins, autophagy-mediated lysosomal turnover has the ability to degrade stable proteins, 
pathogens (xenophagy) and whole organelles such as mitochondria (mitophagy). Much of the 
early understanding on autophagy came from work in yeast. Through unbiased yeast autophagy 
screens the initial network of proteins and biomolecules responsible for autophagy induction 
grew significantly. This early work led to the discovery of human orthologues and an initial 
large-scale study shedding light onto the network organization of mammalian autophagy [1].  
Autophagy is a highly orchestrated, dynamic process that is modulated at several points. 
Autophagy initiation is regulated by a core set of five protein complexes. Classically these can be 
defined as (1) the UNC-51-like kinase (ULK1) complex, made of ULK1, ATG13L, ATG101, 
and FIP200, (2) the VPS34 kinase complex, composed of VPS34 (PI3KIII), VPS15 (PIK3R4), 
Beclin1 and ATG14 or UVRAG, as well as (3) PtdIns(3)P binding proteins such as DFCP1 and 
WIPI1 and (4) the ubiquitin-like conjugation system of ATG5-12 and ATG16L. Furthermore (5), 
microtubule associated protein 1-light chain (LC3) and related ATG8-family protein 
phosphatidylethanolamine conjugation via the ATG5-12-16L system and mATG9-positive 
membranes is required for canonical autophagy [2]. Conjugation occurs through the action of 
ATG4, a cysteine protease, which cleaves the C-terminus of ATG8 family proteins, including 
LC3, GABARAP, GABARAPL1 and GABARAPL2 [3]. Further, ATG7, an E1-like activating 
enzyme activates ATG12 for conjugation to ATG5, allowing for proper membrane targeting of 
LC3 [4]. The list of known kinases and proteins regulating autophagy continues to expand. A 
comprehensive review on autophagy initiation by KL Guan reveals a highly regulated 
multifaceted process that still requires further delineation [2].  See Box 1 for a schematic 
diagram of autoautophagy initiation.  
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1.1 Autophagy in mouse models and cancers 
Genetic studies in mouse have underlined the importance of autophagy network genes in proper 
embryonic development and more recently in cancer progression. Indeed, mice deficient in both 
Ulk1 and Ulk2 die within 24 h of birth. Moreover a bi-allelic deletion of either Atg5 or Atg7 in 
mice results in offspring that cannot survive past the first day following birth. Without Ulk1 or 
Ulk2, Atg5 or Atg7, mice are unable to appropriately maintain energetic homeostasis during the 
first fasting state when maternal nutrition is no longer available [5]. Lethality during this first 
period of perinatal life demonstrates a systematic failure to recycle primary metabolites in an 
autophagic-dependent manner. 
 Interestingly, mice deficient in Ulk1/2, Atg5 or Atg7 all exhibit relatively consistent 
pathological phenotypes. Lung development is severely limited in knock-out mice, and alveolar 
space in the lung is significantly reduced. Additionally, high glycogen levels in the lung were 
observed, although surfactant producing lamellar bodies were unchanged and overall, the ability 
to regulate membrane trafficking was largely impaired. The developmental mechanism 
governing Ulk1/2 and Atg5/7 early post-natal death evidently requires further examination, yet 
present studies indicate ULK1 and autophagy are essential for life and proper development [5].  
Little is known regarding autophagy in the context of cancer although autophagy has 
been suggested to act as both a promoter and a suppressor of tumourigenesis. Evidence of its 
suppressive activity comes from gene deletion studies in mice. These studies demonstrated that 
loss of autophagy promotes the formation of multiple types of benign liver tumours [6]. In 
contrast, blocking autophagy inhibits tumour growth in advanced tumours, suggesting that 
targeting autophagy could have a potential therapeutic role in metastatic disease [7]. In mouse 
models of pancreatic ductal adenocarcinoma, autophagy promotes tumour growth and 
progression [8]. Tumours exhibit elevated autophagy as marked by the accumulation of GFP-
LC3 puncta. Moreover, when autophagy is genetically ablated, either through deletion of Atg5 or 
Atg7, a greater level of tumour initiation is noted, yet lesions were impaired from progressing to 
an invasive cancer type. The connection between autophagy and cancer progression has been 
examined in other cancer types. For instance, in breast cancer patients, high-levels of ULK1 
expression correlate to a reduced likelihood of event-free survival [9]. Furthermore, autophagy 
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appears to have the shared dual role in mouse models of lung cancer that are seen in pancreatic 
cancer models [10].  
1.2 Autophagy mediated by the serine/threonine kinase ULK1 
One major gap in our understanding of autophagy is the list of known substrates for the 
serine/threonine protein kinase ULK1. The ULK kinase family shares little homology with any 
of the other 257 human protein kinases. ULK1 puncta formation is noted as one of the earliest 
events in autophagosome formation. Although the consensus phosphorylation motif of the yeast 
orthologue of ULK1, ATG1, was identified through the generation of a novel synthetic peptide 
library and proteomic screen [11]; a gapped BLaST and alignment reveals no overlap to human 
orthologues of the proteins reported outside of ULK1 itself. Moreover, the suggestion that 
mATG9 is a physiological target of ULK1 in early autophagy remains somewhat unexplained as 
ATG9-positive membranes do not form into phagophores and have not been seen to associate 
with early autophagic proteins such as ULK1. Instead, ATG9 is largely thought to participate at 
recycling endosomes and the endoplasmic reticulum, a late stage in autophagy [12]. 
 
 
Box 1. Interplay 
between amino acid 
signalling, energy 
sensing and 
autophagy. ULK1 
phosphorylates AMPK, 
Raptor, Beclin1, ATG9 
and possibly PIKfyve 
or Sac3. The VPS34 
complex responds to 
both mTORC1 and 
ULK1 for the 
respective repression 
or initiation of lipid 
kinase activity. Ambra1 
is phosphorylated by 
mTOR but also 
stabilizes ULK1. The 
ATG7 E-3 ligase allows 
for the acylation of 
LC3.   
11 
 
The PIKfyve lipid kinase complex converts PtdIns(3)P into the lower abundance phospholipid, 
PtdIns(3,5)P2, which in turn can be converted into PtdIns(5)P. ATG9 is phosphorylated by 
ULK1 to initiate autophagy.  
 
ULK1 mediates its physiological function through its three-domain structure and has a kinase 
domain, a species-variable signalling sensor domain, called a PAS domain, and a conserved C-
terminal domain and in humans there are four related ULK kinases [13, 14]. ULK1 and ULK2 
are the most closely related of the family and have been studied to the greatest extent thus far. 
While the two kinases share a high degree of similarity at the molecular level, they have 
significantly distinct areas of their kinase domain conferring a possibly nuanced autophagy-
specific function. Between the large and small lobes of the kinase domain resides a large loop, 
largely distinct to the ULK family of kinases. Only the Sgk, Wee1, Mlk, Clk and JAK families of 
kinases have a similar structural fold. This loop, although seen across the ULK family, is a noted 
area of distinction between the primary sequence of ULK1 and ULK2, suggesting that there 
could be ULK1-specific mechanisms that govern autophagy, which ULK2 is not readily 
privileged to participate in. However, it is likely that this difference underlies nuanced kinetic 
and thermodynamic differences which dictate functional output [15].  
1.3 ULK1 mutations and clinical findings 
Unfortunately, there have been few reported clinical perturbations of ULK1 conferring altered 
phenotypes to gain true biological insight. Indeed, the Sanger Institute’s Catalog of Somatic 
Mutations in Cancer (COSMIC, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) 
identified fewer than 200 mutations in ULK1 out of over 20,000 somatic tumour samples. While 
insight from the clinic remains limited, mutagenesis studies have readily probed structure-
function relationships of the ULK1 complex. Kinase-inactive ULK1 generated via mutagenesis 
of lysine-to-isoleucine (K48I) exhibit reduced kinase activity. In cell culture, K48I-ULK1 cells 
exhibit lower levels of LC3-lipidation relative to control under serum starvation [16].  From the 
recently identified kinase domain crystal structure of ULK1, this K48I mutation should severely 
disrupt kinase activity while not interfering with higher ordered structural conformation. The 
recent structural elucidation of the ULK1 kinase domain demonstrates that mutating this K48 
residue directly interferes with the ATP-binding coordination site, where this residue lies 
proximal to the interlobe-loop. Mutation to this interlobe-loop is unlikely to manifest major 
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structural changes as it is largely unstructured, while it is thought to confer a more ordered 
structure when ULK1 is part of larger kinase complex with Atg13 and FIP200 [15].  
 
 
1.4. Downstream targets and regulation of autophagy 
The suggested importance of ULK1 has arisen from the requirement of its orthologue in yeast in 
addition to functional studies in mammalian cell culture. Known as Atg1 in S. Cerevisiae, ULK1 
has been studied as a target of growth signalling through the mammalian target of rapamycin 
complex 1 (mTORC1, now more commonly referred to as mechanistic target of rapamycin 
complex 1) and energy sensing via AMP-dependent protein kinase (AMPK). Under serum or 
nutrient-deplete conditions, ULK1 is activated by direct phosphorylation by AMPK at serine-555 
and serine-467 [17]. Additionally, AMPK-dependent phosphorylation of ULK1 at serine-317 and 
serine-777 is required for ULK1 activation in response to glucose starvation. Loss of AMPK or 
the loss of AMPK-phosphorylation sites in ULK1 or ULK2 mimics loss of ULK under nutrient-
limited conditions [18, 19]. Related to input from AMPK, under serum-replete conditions ULK1 
activity is antagonized by mTORC1-mediated phosphorylation at serine-757, and serine-473. 
While the exact structural changes propagated by these phosphorylation events remain 
undetermined, ULK1 kinase activity is significantly decreased and its interaction with AMPK is 
significantly disrupted [18]. mTORC1 also phosphorylates AMBRA1 directly at serine-51 as a 
secondary mechanism to inhibit ULK1 ubiquitination and stability. AMBRA1-mediated lysine-
63 ubiquitination via the E3 ubiqutin ligase, TRAF6, stabilizes and aids the self-association of 
ULK1 [20].  
In addition to receiving functional input from mTORC1 and AMPK, ULK1 also 
negatively feeds back onto these kinases, serving a reciprocal regulatory role. ULK1 and ULK2 
directly phosphorylate the mTORC1 component, Raptor, at multiple sites preventing substrate 
interaction with Raptor and sequential phosphorylation of these mTORC1 substrates [21]. 
Moreover, ULK1 mediates the phosphorylation of all three AMPK subunits to negatively 
regulate its activity, which consequently leads to down regulation of autophagy [22]. Overall, 
these reciprocal regulatory mechanisms allow for fine-tuned signalling between three, multi-
protein kinase complexes and for the proper regulation of growth, autophagy and energy-sensing 
signalling.  
13 
 
Downstream of mTORC1 and AMPK, ULK1 functions to regulate VPS34 at the budding 
omegasome and regulates this protein’s ability to produce low abundance, signalling 
phospholipid phosphatidyl-inositol 3-phosphate [PtdIns(3)P]. Mechanistically, ULK1 
phosphorylates a 51kDa protein, Beclin1, the yeast orthologue of ATG6, as part of the VPS34 
lipid kinase complex. Phosphorylation of serine-15 on Beclin1 is conserved in C. elegans and is 
required for the complete induction of autophagy [23]. Beclin1 is also phosphorylated by AMPK 
at serine-93 and serine-96, demonstrating multiple modes of its post-translational regulation. 
ULK1 is further stabilized by AMBRA1, a WD40 protein and E3-ligase interacting protein, 
linking the ULK complex to the VPS34/Beclin1 complex, although ULK1 interaction with 
AMBRA1 appears to be unchanged with regards to nutrient availability [20] [24]. 
1.5 FLCN, and Birt Hogg Dubé Syndrome—connecting autophagy and disease 
A lesser-studied target of ULK1 phosphorylation is the protein folliculin (FLCN). Germline 
mutations in FLCN are responsible for Birt-Hogg-Dubé (BHD) syndrome, an autosomal, 
dominantly-inherited genetic tumour syndrome, characterized by the development of 
fibrofolliculomas, lung cysts, renal neoplasia and increased cancer risk. The syndrome presents 
in approximately 20% of patients as renal neoplasia, and often presents at late developmental 
stages, or is only identified at the development of renal cancers [25-27]. On a molecular level, 
the gene product responsible for the pathology, FLCN, can act as a classic tumour suppressor; 
however the exact molecular function of the protein, and how its functional loss manifests 
disease, remains largely unknown. The protein has no classic motifs or domains; however, 
truncation mutations have been reported in patients with renal cell carcinoma (RCC) and recent 
work in cells has identified FLCN as a mediator of mTORC1 and growth signalling as well as 
being an AMPK substrate. Previous work has demonstrated that targeted loss of FLCN can result 
in activation or suppression of mTORC1 signalling in a context-dependent manner [25, 28]. 
While FLCN has been reported to act as a GTPase activating protein (GAP) towards RagC/D 
GTPases, directly linking FLCN to nutrient sensing and mTORC1 signalling, FLCN has also 
been reported to act as Rag guanine exchange factor (GEF) [29, 30]. UOK257 cells depleted of 
FLCN undergo metabolic transformation driven by AMPK, yielding PGC1-mediated 
mitochondrial biogenesis. Moreover, loss of FLCN increases reactive oxygen species (ROS) 
production, and increases Hypoxia Inducible Factor (HIF) 1 and 2-regulated gene expression, 
including the up-regulation of vascular endothelial growth factor-A (VEGF-A) to increase 
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vasculature, an increasingly targeted protein for treating renal cancers and reducing the 
angiogenic potential and metastasis of tumours [31, 32]. While FLCN has been shown to interact 
with cell structural elements including tight junctions through an interaction with Plakophilin-4 
to regulate RhoA signalling [33] and at the base of cilia [34] no report to date has taken a 
proteomic approach to identify FLCN binding partners. However, there is a very recent link 
between ULK1 and FLCN as a new potential substrate. The FLCN complex is regulated by 
ULK1, and moreover, autophagy is impaired in tumours associated with BHD [21]. 
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2. Methods 
2.1 Antibodies, plasmids and biochemicals 
Anti-FLCN antibodies were provided by Dr Arnim Pause, McGill University, Canada. Anti-β-
actin, -ULK1, -pS555-ULK1, -pS467-ULK1, -pS757-ULK1, -pS172-AMPK, -AMPK antibodies 
were purchased from Cell Signaling Technology, Danvers, Mass, USA. Anti-Pikfyve (PIP5KIII) 
antibody was purchased from Santa Cruz Biotechnology.  Anti-V5 antibodies were provided by 
Life Technologies and anti-LC3 antibodies were sourced from Nanotools, Teningen, Germany. 
Flag (clone: M2) and anti-V5 were obtained from Sigma-Aldrich as well as formic acid solution, 
acetonitrile, trifluoroacetic acid, Phos-Select IMAC resin. The ULK1-inhibitor, QG000052, and 
pS30-Beclin1 antibody was a kind gift of Dr. James Murray, Trinity College Dublin. Radio-
labelled ATP was sourced from Elmer Perkins, Waltham Mass, USA. Full-length ULK1, 
ATG13, BECN1, FLCN, were cloned in-line with GST in a pCMV promoted vector, or 
purchased through Addgene, and validated by sequencing prior to use. The vector to myr-FLAG-
PIP5KIII was purchased through Addgene. BHD-shRNA was generated using Mission shRNA 
constructs (purchased from Sigma-Aldrich Company Ltd.). 
 
2.2 Cell Culture, transfections and immunoprecipitations 
UOK257, HK2 and HEK293 cells were cultured at 21% oxygen, 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal calf serum, 100 U/ml 
penicillin and 100 mg/ml streptomycin (Gibco, Paisley, UK). Cells underwent starvation either 
in Krebs Ringer Buffer (135mM NaCl, 5mM KCl, 1mM MgSO4, 0.4mM K2HPO4, 20mM 
HEPES, pH7.4), Hanks Balanced Salt Solution (Gibco), or remained in DMEM. Transfections 
were performed with JetPEI reagent according to the manufacturer’s protocol (Polyplus, New 
York). To immunoprecipiate proteins from whole cell lysates, 2.5µL of primary antibody was 
added to 500µg of clarified protein in lysis buffer and rocked overnight at 4ºC. To each sample, 
30µL of a 50% slurry of protein-G sepharose was added and allowed to rock for at least 45 
minutes at 4ºC. Immune complexes were subsequently spun down by centrifugation for 4 
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minutes at 2000 x g at 4ºC and washed four times in lysis buffer prior. Proteins were eluted with 
the addition of SDS-PAGE sample buffer and boiling at 95ºC prior to loading in pre-cast or in-
house made SDS-PAGE gels. GST-containing constructs were rocked overnight in 15µL of a 
50% slurry of glutathione-sepharose. Bound complexes were washed in PBS and free GST was 
added at 1mg/mL in 50mM Tris HCl, pH8, to elute bound proteins.  
 
2.3 Luciferase reporter assays  
HK2 cells deficient in FLCN through shRNA knockdown were plated on 96-well plates. 
Luciferase reporter constructs SBE4 (pGL4.48[luc2P/SBE/Hygro]) and NF-κB 
(pGL4.32[luc2P/NF-κB-RE/Hygro) (Promega, Madison, Wisconsin) and a renilla-luciferase 
transfection control were co-transfected with an equimolar amount of pcDNA3 or cDNA to wild-
type and mutant HA-FLCN constructs. To stimulate reporter activity TGF-β was added to 
1ng/mL and reactions incubated for 6 hours prior to fluorescence visualization on a plate reader.  
2.4 Western blotting and in vitro kinase assays 
Cells were washed and then lysed from plates using lysis buffer (20mM Tris, 135mM NaCl, 5% 
(v/v) glycerol, 50mM NaF and 0.1% (v/v) triton X-100, pH 7.6 supplemented with complete 
mini protease inhibitor cocktail (Roche Diagnostics Ltd. Burgess Hill, UK) at 4ºC. After 
centrifugation at 17,000 x g for 10min at 4ºC samples were prepared in 4X NuPAGE sample 
buffer (Invitrogen, Paisley, UK) with 25 mM DTT and boiled at 70ºC for 10 min. Proteins were 
separated by electrophoresis using the NuPAGE gel system (Invitrogen) and transferred to 
polyvinylidene difluoride membranes (Millipore, Watford, UK), blocked in 5% (w/v) dry milk 
powder/Tris-buffered saline 0.1% (v/v) tween, then probed using the required primary antibody 
and horseradish peroxidase-conjugated secondary antibody in Tris-buffered saline Tween. 
Proteins were visualized using Enhanced Chemiluminescent solution and X-ray film (both from 
GE Healthcare, Buckinghamshire, UK). Unless otherwise stated, Western blots were conducted 
in biological duplicate. 
 To perform in vitro kinase assays, proteins were purified following overexpression in 
HEK293 cells. Kinase-substrate reaction mixtures were incubated with radiolabeled ATP for 10 
minutes and quenched with SDS-PAGE sample buffer. Kinase assay experiments were 
conducted in biological triplicate.  
2.5 Peptide Preparation for Mass Spectrometry  
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NuPAGE gels (Invitrogen) used in mass spectrometry analyses were stained directly with 
Coomassie blue, destained with ddH2O, and gel bands were subjected to in-gel tryptic digestion, 
as previously described (Ballif et al., 2006).  
For experiments using stable-isotope labelling by amino acids in cell culture (SILAC 
[35]), HEK293 cells were grown for at least one week in DMEM deficient in L-arginine and L-
lysine (Cambridge Isotope Laboratories, Inc., Andover, MA), but supplemented with 10% 
dialyzed fetal bovine serum (Hyclone); 50 U/ml penicillin and 50 mg/ml streptomycin 
(Invitrogen); and either 73 mg/L unlabeled L-lysine and 42 mg/L unlabeled L-arginine, or 73 
mg/L 13C6-L-lysine and 42 mg/L 13C6-, 15N4-L-arginine (Cambridge Isotope Laboratories, 
Inc.). 15cm
2
 plates of labelled HEK293 cells were washed and starved for 10 min in Krebs 
Ringer Buffer. Heavy labelled plates were supplemented with ULK-inhibitor at 10µM. Cells 
were lysed in lysis buffer 20mM Tris, 135mM NaCl, 5% (v/v) glycerol, 50mM NaF and 0.1% 
(v/v) triton X-100, pH 7.6 supplemented with complete mini protease inhibitor cocktail (Roche 
Diagnostics Ltd. Burgess Hill, UK) at 4ºC, and snap frozen. An aliquot of each sample was taken 
for western blotting and Bradford Assays to normalize protein levels.  
Following protein normalization, heavy- and light-labeled lysates were combined for 2 
biological replicates and resuspended in ice-cold urea lysis buffer (7.99 M urea, 100 mM NaCl, 
25 mM Tris pH8.0, 25 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 50 mM β-glycerophosphate, 
1 mM PMSF, 1 mM leupeptin and 1 mM pepstatin). Lysates were sonicated for 3x 1 min 
intervals at 4ºC in a sonicating water bath at 4
o
C. Insoluble debris was then spun down by 
centrifugation for 30 min at 15000 x g. DTT was added to 5 mM and the clarified lysate was 
incubated at 56ºC for 40 min. Samples were then reduced with 14 mM iodoacetamide for 1 h in 
the dark, quenched with DTT to a final solution concentration of 10mM. Samples were then 
diluted at 1:4 in 25 mM TRIS pH8.0, reducing the urea concentration below 1.6M. Proteins were 
digested with the addition of sequencing-grade modified trypsin (Promega, Madison, Wisconsin) 
at 1:100 overnight at 37ºC. Following digestion, trypsin was pH-inactivated with trifluoroacetic 
acid (TFA) to 0.4%. Cellular debris was then removed from the digest via centrifugation at 4000 
x g for 20 min at 4ºC. The supernatant from biological replicates was desalted on Waters tC18 
columns (pre-conditioned by wetting with 100% acetonitrile (MeCN), equilibrated with 0.1% 
TFA, and eluted in 40% MeCN/ 0.1% TFA), and dried via lyophilization prior to fractionation 
and phospho-peptide enrichment. 
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Labelled peptides were subjected to strong-cation exchange (SCX) coupled to 
immobilized-metal affinity chromatography (IMAC). Briefly, dried peptides were resuspended 
in SCX buffer A (7mM KH2PO4 pH2.65, 30% MeCN) and applied to a polySULFOETHYL A 
solid phase extraction column (PolyLC Inc, Columbia, MD) pre-equilibrated with a blank run of 
80%MeCN, water, followed by SCX buffer A for over 30 min. Peptides were fractionally eluted 
with 6ml fractions of SCX solvent B (7mM KH2PO4 pH2.65, 30%MeCN, 350mM KCl) adjusted 
with SCX solvent A to the following concentrations of KCl: 0, 4, 8, 12, 25, 90 and 250mM. 
Peptides were frozen at -80ºC, lyophilized, and then desalted on tC18 columns and dried as 
previously described.  
Peptides from each SCX fraction were re-suspended in 100µl of 40%MeCN/25 mM 
formic acid (FA) and 40µl of a 50% slurry of Phoselect IMAC resin (SIGMA) and then 
vigorously shaken for 1hr at room temperature. An additional 50µl of re-suspension buffer was 
added to each fraction, and samples were loaded onto home-made crimped, 200µl gel-loading 
tips. Flow-through was collected and re-applied to the IMAC resin 3 times prior to washing 
twice with 120µl re-suspension buffer. Phosphopeptides were eluted with 50mM K2HPO4 pH10, 
and pH neutralized with 10% FA. Peptides were spun to dryness. 
2.6 Mass Spectrometry 
Peptides from SILAC and pull-down studied were resuspended in 2.5%MeCN/ 2.5%FA and 
loaded for nano-scale microcapillary LC-MS/MS in an LTQ Orbitrap Discovery mass 
spectrometer (Thermo Scientific), fitted to a Finnigan Nanospray II electrospray ionization 
source, an MS Pump Plus HPLC pump and a Thermo Micro AS autosampler (Thermo 
Scientific). Peptides were separated on an increasing gradient of 99.0% MeCN and 0.15% FA 
(Solvent B) from 15 to 60 min on a 100µm internal diameter, in-house prepared 13cm long C18 
reverse phase resin (MagicC18Q, Michrom Bioresources, Auburn, CA) with a needle tip 
diameter of ~5µm.  
Initial peptide mass identification and quantification was conducted with an MS1 full 
scan followed by 10 MS/MS scans in a data-dependent fashion. Peptides were identified using 
the SEQUEST and MASCOT algorithm (Thermo Electron Version 27 Revision 12) (Eng et al., 
1994) (www.matrixscience.com) against the human international protein index (IPI) database 
(Human IPI v6.60.fasta) in a target-decoy approach [36], allowing for phosphorylation of serine, 
threonine or tyrosine (+79.96633 Da), oxidized methionine (+15.99429 Da), 
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carbamiodomethylated cysteine (+57.02146 Da). For SILAC studies, searches also required 
differential labelling of lysine (+8.014198 Da) or arginine (+10.008268 Da) and for reductive 
amination chemical labelling studies, searches required addition of dimethylation (+28.0313) and 
allowed for differential mass addition of deuterium.  
2.7 Bioinformatics  
MS runs were initially filtered below a 0.5% peptide-level false discovery rate using an 
automated linear discriminant analysis weighted by Xcorr, Cn, MS2 ion intensity, missed tryptic 
cleavages, adjusted precursor PPM and peptide length. The Ascore algorithm was employed to 
confidently assess phosphorylation site localization on a given peptide based on probabilistic 
likelihood as described previously [37]. Phosphopeptides were required to have a minimum 
Ascore of 3, correlating to greater than 80% confidence in the localization of a particular 
phosphorylation site. The resultant non-quantitative, quantitative, and phospho-specific datasets 
each had estimated false discovery rate (FDR) below 1%. The DAVID bioinformatics software 
resource and manual, informed filtering strategies were used to examine protein lists and identify 
enriched protein categories, gene ontologies and biological processes. 
 
 
 
 
3. Results 
3.1 ULK1 pull-downs and purification strategy 
Identifying interacting partners of ULK1 has remained fairly elusive. Low protein expression 
levels, viability of cells over-expressing the kinase, and the temporal dynamics of autophagy 
have all contributed to a limited understanding of the kinase. Therefore, prior to examining 
ULK1 interactions, we first optimized transfection and immuno-affinity enrichment strategies. 
As ULK1-mediated autophagy is thought to occur as early at 15 min following complete 
withdrawal of nutrients [38], several time points and ULK1 constructs were examined to judge 
relative levels of ULK1 that could be purified. To enrich for ULK1 in vivo, 90% confluent 25cm 
plates of HEK293 cells were transfected with plasmids to express GST-ULK1 or the kinase-
inactive mutant, GST-ULK1
K48I, and were starved in Kreb’s Ringer Buffer (KRB) for 18h. 
ULK1 binding partners were resolved by SDS-PAGE following GST purification and 
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subsequent wash steps (Figure 1a). In addition to GST-ULK1, untagged and V5-ULK1 was 
examined by immunoaffinity enrichment; however, these enrichments were observed to purify 
significantly less ULK1 and had greater non-specific binding as judged by background bands 
seen in the control lane (Figure 1b, Supplemental Table S1, S2). While a high degree of 
background was identified through immunoaffinity enrichment, a greater number of unique 
bands were also identified. Therefore, both GST and V5–tagged protein interacting bands were 
excised and subjected to protein identification by mass spectrometry.  
3.2 Identification of novel ULK1 binding partners 
Following separation by SDS-PAGE, control, wild-type and K48I kinase-inactive ULK1 mutant 
lanes of the gels were excised and examined by mass spectrometry. After peptides and proteins 
were identified, a cut-off to only include proteins identified by more than one peptide was used 
to exclude possible contaminating proteins. Some validated ULK1 binding partners, including 
AMPK subunits, were only identified by one peptide in the K48I pull-down. While this set cut-
off excludes likely bona fide ULK1 interacting partners, it also significantly reduces the rate of 
false positive identifications.  
A greater amount of total GST-ULK1 was purified from cells compared to V5-ULK1, yet 
a similar number of interacting partners were identified by this purification method in total. 
Filtering peptide identifications below a 2% FDR, we identified 194 ULK1 peptides from GST-
WT-ULK1 pull-down, and 82 peptides from GST-KI-ULK1 pull-down. Several hundred 
proteins were identified as GST-WT and GST-KI-ULK1 interacting proteins; however, many of 
these are likely contaminants, including keratin proteins (Supplemental Table S2, S3). 
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D) V5-WT-ULK1 and FLAG-PIKfyve were co-expressed in HEK293t cells and incubated in 
either Krebs Ringer Buffer or DMEM. The V5 tag was immunoprecipitated from lysate and pull-
downs were blotted for with antibodies against Flag and V5 epitopes.  E) To further confirm 
ULK1 binding to PIKfyve, endogenous ULK1 was immunoprecipitated from HEK293t cells 
using a Santa Cruz Biotechnology antibody (F4) or a Cell signalling antibody* (D8H5). 
Following pull-down by SDS-PAGE, endogenous PIKfyve and ULK1 protein levels were then 
probed for by Western blot. 
 
 Indeed, a control pull-down of GST alone identified contaminants, where high levels of 
keratin and known contaminants such as trypsin were found. To get around contamination and 
discover more possible biologically relevant ULK1 interactions, we next looked at proteins that 
associated with V5-ULK1. From this purification a total of 201 ULK1 peptides were identified at 
an FDR of 2%. In total, 315 proteins were identified as potential ULK1 binding proteins by 
greater than 3 total peptides, although these proteins remain to be validated by traditional 
approaches (Supplemental Table S1).  Expert bioinformatics work and manual interrogation with 
75kDa 
25kDa 
150kDa 
Figure 1. Identification and 
validation of novel ULK1 
Substrates 
A) HEK293t cells were 
transfected transiently with 
vectors to pCDNA3 alone or with 
pCDNA3 containing GST-WT- or 
GST-K48I-ULK1 respectively. 
Following transfection, cells were 
starved in Krebs Ringer Buffer for 
18hrs prior to lysis. 
Overexpressed ULK1 and its 
binding partners were captured by 
immunoaffinity enrichment 
separated and visualized 
following SDS-PAGE and 
coomassie stain. B) Control (IgG 
alone) and anti-V5 pull-down 
lanes were excised and protein 
bands were identified by mass 
spectrometry, as was done in A. 
C) The top biologically relevant 
ULK1 interacting partners are 
given. The entire gene list of 
ULK1 binding partners can be 
found in Supplemental Table 1. 
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prior knowledge of autophagy and endosomal biology is critical for selecting proteins having a 
high probability of bona fide interactions with ULK1.  
In addition to known ULK1 substrates such as AMPK (PRKAA) subunits PRKAG1, 
PRKAG2, FLCN, FIP200, ATG101 (C12orf44), and SYNGAP1, we identified previously 
unreported substrates which likely participate in various aspects of autophagy, including PIKfyve 
(PIP5K3), a lipid-binding phosphoinositide kinase responsible for enzymatically turning 
PtdIns3P to PtdIns(3,5)P2 and PtdIns(5)P with the adapter proteins, Sac3 and ArPIKfyve, also 
identified in our screen. We also identified ASAP1, an ArfGAP with an SH3 domain, and a 
number of proteins that participate in early endosomal biology including TBC1D9, a RabGAP 
(Supplemental Table S3). Another early endosomal protein which could play a hand in the 
regulation of autophagy that we identified in our screen is LYST, the lysosomal trafficking 
regulator protein, which is thought to be responsible for packing materials into lysosomes [39]. 
The LYST protein also plays a role in autophagosome maturation, whereby loss of LYST results 
in compromised immune signalling and oversized autophagosomes [40].  Moreover we identified 
VPS26, VPS33, and VPS54, involved in retrograde transport from endosomes to the trans-Golgi 
and endolysomal transport [41, 42]. Through the identification of all of these candidate proteins, 
it is likely that ULK1 has a hand in fine-tuning the response of vacuole dynamics and endosomal 
biology to a greater extent than once thought. 
The ArfGAP, ASAP1, functions at the budding primary cilia to regulate receptor 
targeting. As a GTPase activating protein, ASAP1 binds to and serves as a scaffold for the 
Rab8/Rabin8 complex, responsible for initial vacuole formation in ciliogenesis. This process is 
largely analogous to the requirement of small G-proteins in autophagy and may illustrate an 
evolutionary mechanism by which ULK1 functions upstream of vacuole formation and extension  
(Figure 1C, Supplemental Table S1) [43-45]. Interestingly, ULK1 substrates that have been 
identified as targets of its kinase activity, such a Beclin1, were found only as minor binding 
partners in our screen (Supplemental Table S1).  
We also identified substrates that have no acknowledged role in autophagy including 
RSK4 (RPS6KA6), which suggests further roles for ULK1 outside of its canonical pathway. 
RSK4 is a 90-kDa serine/threonine kinase of the ribosomal s6 kinase family (RSK), which is 
constitutively active in most cell types [46] (Supplemental Table S1). Unlike the rest of the RSK 
family of protein kinases, RSK4 is thought to participate in growth factor independent pathways. 
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A 2005 paper identified several phosphorylation sites on RSK4, one of which was serine-232 
that may be an ULK1 site due to the fact that the yeast Atg1 consensus motif closely matches 
this phosphorylation site. Additionally, distinct from the other phosphorylation sites identified in 
this report, serine-232 displayed a nearly inverse pattern of regulation compared to the other sites 
identified [46].  
 Although a number of the targets identified by proteomic methods could be functionally 
interrogated, PIKfyve was selected because it was a top scoring binding partner identified in 
wild-type and kinase-inhibited ULK1 screens and we identified its binding partner ArPIKfyve 
(VAC14), to a lesser extent. Additional pull-downs with GST-tagged ULK1 also identified 
PIKfyve (data not shown). Mechanistically, PIKfyve takes the product of the ULK1-regulated 
VPS34 complex, PtdIns(3)P and adds a phosphate to create another, less abundant second 
messenger, PtdIns(3,5)P2 [47]. The exact role of ULK1 association with PIKfyve is still 
unknown; however, we find a greater association with wild-type ULK1 to PIKfyve under 
nutrient limited conditions than in nutrient-replete conditions, suggesting it has a functional role 
mediated by ULK1 activity (Figure 1d). In addition to using over-expressing constructs of 
ULK1, we also analysed binding of endogenous proteins. We observed that endogenously 
purified PIKfyve bound to ULK1 in HEK293 cells, solidifying the interaction as a real, in vivo 
candidate for functional characterization (Figure 1e).  
3.3 ULK1 phosphorylation targets and quantitative proteomics 
A recent study in yeast identified Atg1 phosphorylation sites by screening a peptide library and 
using mass spectrometry following incubation with the kinase to determine linear-motif substrate 
specificity [11]. They reported the preferred phosphorylation motif of Atg1 as LxxSxYxP, and 
validated this substrate specificity with several yeast proteins and human Beclin1. However, an 
independent analysis of the human orthologues identified through BLAST and subjected to a 
sequence alignment with the ClustalW2 program (http://www.ebi.ac.uk/Tools/msa/clustalw2/), 
reveals that only ULK1 at a novel site (517) has a residue which could be phosphorylated out of 
the candidate yeast protein identified in this study (Figure 2). The rest of the yeast proteins 
remain distinct from human orthologues in their sequence similarity and possible, modified sites. 
Although this disparate result is somewhat surprising due to the assumed and previously reported 
level of evolutionary conservation in autophagy, it is at least partially supported by the wide 
variety of ULK1 sites reported [48]. However this comparative analysis raises the question of 
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whether a unique human ULK1 phosphorylation motif exists, and how similar ULK1 
mechanisms are between species with regards to the conservation of autophagy-associated 
proteins. Therefore, to probe this question and look for human ULK1 substrates, we looked to 
identify ULK1-mediated phosphoproteomic changes using quantitative mass spectrometry and a 
novel ULK inhibitor. 
 
 
3.4 Inhibitor validation in vitro and in vivo 
Many previous studies have employed similar inhibitory mechanisms and peptide libraries or 
quantitative proteomics to identify consensus kinase motifs. One example is the use of rapmycin 
and torin-1 as pharmacological inhibitors of mTOR in a quantitative phosphoproteomic 
workflow to identify the mTOR kinase motif [49]. Analogous to this previous study, we ventured 
to use a novel inhibitor of ULK1, QG000052, to examine ULK kinase-dependent modifications 
Figure 2. ClustALW2 multiple 
sequence alignment highlights 
disparity between yeast atg1 and 
human ULK1 phosphorylation 
sites 
Uniprot accessions from high 
confidence phosphorylation sites 
identified by Papinski et al 2014 
were used to identify orthologous 
human proteins through a gapped 
BLAST search 
(http://blast.ncbi.nlm.nih.gov). The 
gene identified in this study is 
given in lowercase lettering, with 
yeast phosphosite number 
provided, followed by the 
corresponding human gene symbol 
and aligned sequence. Orthologous 
protein sequences were then 
compared to identify conserved 
phosphorylation sites or motif 
overlaps using a multiple sequence 
alignment with ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/cl
ustalw2). 
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in vivo. As the ULK1 inhibitor used in this study has not yet been published and characterised, 
we first endeavoured to validate its effectiveness in vivo. Prior to attempting to inhibit ULK1 in a 
large-scale screen, we initially validated the ULK1 inhibitor, through in vitro kinase assays and 
by western blot. To generate substrates, GST-tagged ATG13, ULK1 and BECN1 were grown 
and purified from HEK293t cells. By incubating ULK1 in the presence of QG000052 in vitro, 
ULK1 autophosphorylation and phosphorylation of the validated human targets of ULK1, 
ATG13 and BECN1, were significantly reduced relative to uninhibited ULK1 kinase. 5µM 
QG000052 treatment resulted in 20% kinase activity of ULK1 relative to the control, 
demonstrating the potency of the inhibitor (Figure 3a). Interestingly a site on BECN1, serine-30, 
does not seem to be significantly affected by ULK1 treatment nor inhibition, although total 
BECN1 phosphorylation is significantly reduced by QG00052 treatment. This is likely due to 
changes in the known ULK1 phosphorylation site on BECN1, serine-15 [23]. 
Next we evaluated the inhibitor in the context of the functional ULK1 complex. 
Following immuno-precipitation of ULK1 from HEK293 cells treated with QG000052 in full 
media (DMEM) or in Krebs Ringer Buffer for 1h, ULK1, FIP200 and ATG13 were probed for 
by western blot. Relative to control conditions, the inhibitor did not significantly disrupt the 
association (Figure 3b). To further examine ULK1-mediated changes upon inhibition, live-cell 
imaging was performed on GFP-WIPI1 transiently transfected U2OS cells (courtesy of the 
Murray laboratory). The WIPI1 construct was used as it binds to PtdIns(3)P by virtue of its 
FYVE domain to create discrete puncta and can be used to track VPS34 activity and the level of 
autophagy temporally and quantitatively in cells [50]. WIPI1-positive puncta formation 
decreased significantly upon QG000052 treatment at 20µM relative to control conditions of 
amino acid withdrawal. Inhibition of puncta formation in ULK1 inhibitor treated cells mimicked 
results seen with the known autophagy and lipid kinase inhibitor wortmannin (Figure 3c).  
3.5 Temporal initiation of autophagy and ULK1 activity and workflow 
Previous research has demonstrated that autophagy is a temporally dynamic process and the 
coordination between LC3 positive puncta, ATG5-12 conjugation and Beclin1 presence can 
occur in less than 15 min [38]. However, many studies examining ULK1 and the dynamics of 
autophagy often starve cells of nutrients for over 18h. Chronic starvation achieves a robust 
signal, but significantly lacks any physiological relevance. Therefore, prior to examining the 
effects of QG000052 en masse we performed several time course experiments to determine the 
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most appropriate time to inhibit ULK1 kinase activity. Supported by published temporal 
observations, we notice changes in autophagy as early as 15 min following complete starvation. 
We identified a significant change in LC3 lipidation as early as 15min (Figure 4a). Lipidation of 
LC3 can be visualized by a molecular weight shift to a lower, distinct band by Western blotting.  
A 30min time course was ultimately chosen as a point of known, active autophagy, but a point 
where negative feedback secondary mechanisms mediated by mTORC1 and AMPK 
phosphorylation would be less confounding relative to longer time points.  
 
 
 
In order to quantitatively compare starved wild-type cells to starved cells treated with 
QG000052, stable isotope labelling was performed to induce a mass difference that could later 
be tracked through a mass spectrometry based approach [35]. Cells were grown in media 
containing stable-isotope labelled lysine and arginine for 3 passages, across experimental and 
Figure 3. QG000052 potently 
inhibits ULK 
autophosphorylation and 
kinase activity towards 
known substrates in vitro and 
in vivo  
A) Representative Western and 
32P-y-ATP incorporated blots 
of ULK1, ATG13 and BECN1 
with densitometry given below 
blots (n=3).  B) ULK1 binding 
assays was performed with and 
without the presence of the 
ULK1 inhibitor, QG000052, 
under nutrient limited 
conditions to assess the impact 
of inhibition on ULK1-complex 
formation. C) GFP-WIPI1 
puncta, a marker of autophagy, 
was assed in full media (CM) or 
following nutrient withdrawal 
in U2OS cells treated with 
wortmannin (WM) or the 
ULK1 inhibitor QG000052.  
Puncta formation can be clearly 
seen in cells starved with 
Earle’s Balanced Salt Solution 
(EBSS) alone.  
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control conditions (Figure 4b). Following complete metabolic labelling, light-labelled cells were 
starved for 30min in KRB and given DMSO as a mock control and heavy-labelled cells were 
starved for 30min in KRB and supplemented with 20µM QG000052.  
Following lysis of two biological replicates, protein concentration was determined by 
BCA and normalized across biological replicates and between experimental conditions. To 
validate the action of the ULK1 inhibitor in vivo and ensure metabolic labelling did not have 
secondary effects, we probed for pS30 Beclin1, pT172 AMPK, AMPK, ULK1, pS555 ULK1, 
pS755 ULK1, pS476 ULK1, pS859 Raptor, p62/Sequestrin and β-Actin as a loading control 
(Figure 4c). Importantly, treatment of cells with QG000052 is seen to reduce the ULK1 
phosphorylation of Raptor at Serine-859, but does not significantly perturb the phosphorylation 
of ULK1 or AMPK. Interestingly phosphorylation of Beclin1 at serine-30 was not significantly 
reduced. ULK1 phosphorylation at Serine-555 is somewhat reduced, which may be explained by 
conformational changes brought about by the inhibitor, however other ULK1 phosphorylation 
sites remained unchanged following drug treatment (Figure 4c).   
3.6 Quantitative results 
The quantification of identified peptides was performed in the full scan of the mass spectrometer 
prior to the collision-induced dissociation (CID) of peptides into fragment ions to allow peptide 
identification. This technique readily allows for the quantification of peptides from the binary 
experimental conditions, as peptides share the same ionization efficiency in the gas phase, and 
co-elute from nano-liquid chromatography [35]. We further optimized this technique for our 
experiment to confidently detect a large number of peptides and allowed for the ten most 
abundant ion species to be dissociated following a full scan. This ‘top-10’ technique comes as a 
relative compromise to only selecting the three most abundant species in a scan in terms of 
abundance fragment ions and subsequent peptide identification, but it has been highlighted 
previously in phosphoproteomic screens to detect the greatest number of total proteins [45]. 
Due to technical issues with the Immobilized Metal Affinity Chromatography (IMAC) 
step to enrich for phosphopeptides, few phosphopeptides were identified as compared to similar 
phosphoproteomic screens. In total we identified 270 phosphorylation sites, including sites in the 
proteins RPLP1, XRN2, NUCKS1, SYNE1, SRRM1, PSMA3, and LRRC16A. While ULK1 
inhibitor-mediated changes were identified, data collection did not produce results which could 
be analysed confidently to reflect the underlying biology of the system. It is likely that the SCX-
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IMAC step led to subsequently poor data collection as we identified a similar number of proteins 
between biological replicates but were not able to identify a large number of proteins in early 
fractions of SCX as expected (Figure 4d).  
 
 
lysates from inhibitor-treated and control plates was normalized by Bradford assay according to 
the manufacturers protocol (Piercenet), and combined at a 1:1 ratio. Reactive cysteines were 
reduced with DTT and alkylated with iodoacetamide prior to a tryptic digest with a trypsin to 
lysate ratio of 1:100. Tryptic peptides were purified from enzyme and Urea and subjected to 
fractionation by strong-cation exchange (SCX). Each fraction then underwent phosphopeptide 
enrichment via immobilized metal affinity chromatography (IMAC). Peptide and buffer 
impurities were removed and peptides were concentrated prior to quantitative mass spectrometry. 
C) Prior to enzymatic digestion with trypsin, the relative inhibition of ULK1 kinase activity 
towards known interactions and normalization of protein concentration was examined by 
Western blotting. D) Following SCX-IMAC workflow, peptides were grouped by SCX fraction 
Figure 4. SILAC-based 
workflow to identify ULK1-
mediated phosphoproteomic 
changes 
A) HEK293 cells were 
starved of nutrients in KRB 
for each experimental time 
point with or without the 
ULK1 inhibitor. Cells were 
immediately lysed on ice and 
flash frozen in liquid 
nitrogen. Total LC3I/II levels 
were probed for by Western 
blot. B) HEK293 cells were 
allowed to incorporate stable-
isotope labeled amino acids 
(either un-labeled lysine and 
arginine [K0/R0] or heavy 
labelled lysine and arginine 
[K6/R8]) for 4 passages prior 
to cell-based experimentation. 
Six 25cm plates were cultured 
to 90% confluency and 
starved for 30 minutes with 
KRB in the presence or 
absence of QG000052. Cells 
were lysed in ice-cold 8M 
Urea lysis buffer complete 
with protease and 
phosphatase inhibitors. Cell 
lysates from inhibitor-treated 
and control plates was 
normalized by Bradford 
Assay according to the 
manufacturers manufacturers 
protocol (Piercenet), and 
combined at a 1:1 ratio. 
Reactive cysteines were 
reduced with DTT and 
alkylated with iodoacetamide 
prior to a tryptic digest with a 
trypsin to lysate ratio of 
1:100. Tryptic peptides were 
purified from enzyme and 
Urea and subjected to 
fractionation by strong-cation 
exchange (SCX). Each 
fraction then underwent 
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to determine the number identified in each sequential increase in KCl for each biological 
replicate (BR1 and BR2). 
 
 
Therefore, we compared total protein level changes in response to QG000052 treatment as a 
proof-of-principle experiment (Figure 5). In total, we confidently identified 464 proteins by at 
least two peptides. In addition to identifying a number of housekeeper proteins such as histones, 
cytoskeletal proteins and chaperones, we also identified signalling proteins such as DNA-PKc 
and ARF1 (Supplemental Table S4). With a functional workflow validated, this experiment could 
quite easily be repeated to discover the ULK1 phosphorylation motif.  
 
 
 
Figure 5. Bivariate density analysis plotting the measured mass accuracy of the precursor 
phosphopeptide ions (in ppm) with peptide Log2(Treated/Untreated) SILAC ratios  
All phosphopeptides from the two biological replicates were plotted based on mass accuracy of 
peptide identification (mass accuracy) and peptide quantification (Log2(QG000052-
Treated/Untreated) ratio). Indicated are QG000052-upregulated and -downregulated peptides. 
The data inside of the lowest bivariate density curve represents 90% of all phosphopeptides, with 
minor lines corresponding to 5% density differences. 
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Chapter II 
Novel biology of the tumour suppressor FLCN  
 
3.7 Identification of novel FLCN binding partners and validation in vivo 
In addition to identifying novel ULK1 binding partners, we sought to identify binding partners to 
the ULK1 target, FLCN, due to its role in disease and the reported discrepancy of its function in 
autophagy. Further, as we identified FLCN as an ULK1 interacting protein, it became a more 
attractive target to elucidate. To identify new FLCN binding partners, GST-tagged human FLCN 
was overexpressed through transfection into HEK293 cells.  Following lysis, GST-FLCN and its 
interacting partners were purified on glutathione-Sepharose resin and resolved by SDS-PAGE 
(Figure 6a). Gel bands were excised, proteolytically digested, and proteins were identified by 
mass spectrometry. We confidently identified known FLCN interacting partners such as 
GABARAP, FNIP1 and FNIP2, and in total identified over 100 novel FLCN interactions with 
high confidence based on protein coverage and number of mass spectra identified (Supplemental 
Table S5).  
The list of proteins identified by mass spectrometry was subjected to bioinformatics 
analysis to discover gene ontology enrichments in an unbiased fashion. We used the DAVID 
bioinformatics program to specifically identify enriched molecular functions and protein 
domains found in the FLCN-interactome whose significance was determined as a function of 
gene ontology p-values (Figure 7a and 7b, Supplemental Table S6 and S7). Supporting recent 
results from other labs to suggest the role of FLCN as a modulator of autophagy and mTORC1 
signalling, we identified proteins involved in translational elongation as FLCN-binding proteins. 
These include ribosomal proteins and EEF1A2. Moreover, FLCN may play a role in transport, as 
suggested by binding proteins with a HEAT domain. HEAT domains are long solenoid domains 
composed of alpha-helical bundles that are found in transport proteins including huntingtin 
(HTT) and protein phosphatase 2 (PP2a). HEAT domain-containing proteins that we identified 
include but are not limited to HTT, CKAP5, IMO5, HEATR1, PPP2R1A, BTAF1, and ATR 
(Supplemental Table S7).  
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Figure 6. FLCN is heavily phosphorylated at proline-directed serine residues) To identify 
FLCN phosphorylation sites and potential kinases HEK293 cells were transfected with full 
length GST-FLCN and untreated, or treated with insulin (INS), Rapmycin and insulin 
(RAP/INS), LY and insulin (LY/INS), 2-Deoxy-glucose alone (2DG), or 2-Deoxy-glucose and 
compound C (2DG/CC).  FLCN and its interacting partners were then GST-purified, separated 
by SDS-PAGE and visualized by coomassie brilliant blue staining. A total of six bands were 
excised from each lane, with care to isolate the large GST-FLCN band by itself. B) 
Phosphorylation sites identified and localized by LC-MS/MS for each experimental condition are 
provided. Site numbering follows the SwissProt-reviewed full-length protein sequence. The full 
mass spectrometry-based dataset for FLCN phosphorylation sites is provided in Supplemental 
Table S6 and S7).  
 
3.8 Identification of FLCN phosphorylation sites and modulation by pharmacological 
inhibition 
In order to understand possible functional roles of FLCN, cells were treated with various 
signalling pathway inhibitors and then FLCN phosphorylation sites were identified by mass 
spectrometry. HEK293 cells over-expressing GST-FLCN were left untreated or treated with 
insulin, insulin and rapamycin (mTORC1 inhibitor), insulin and LY294002 (PI3K inhibitor), 2-
deoxyglucose (glycolysis inhibitor), or 2-deoxyglucose and Compound C (AMPK inhibitor). Gel 
bands corresponding to GST-FLCN were excised and digested with trypsin. In order to identify 
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FLCN phosphorylation sites, spectra generated by mass spectrometry were matched to either the 
full-length FLCN protein or its reverse sequence as a target decoy approach to reduce false 
peptide sequence assignments. The Sequest search algorithm, which employs a cross correlative 
strategy, was used to asses the number and validity of matching fragment ions from experimental 
against the same theoretically generated spectra. In effect, the algorithm provides a peptide 
sequence identity for each spectra based on a statistical framework and can be evaluated and 
manually validated by expert analysis. The forward and reverse amino acid sequence of the full-
length FLCN protein was utilized so peptide assignments arising from the known-wrong 
(reverse) sequence could be used to assess the percentage of unknown-wrong assignments.  
Although trypsin was used as the proteolytic enzyme to generate peptides, we allowed for no 
specific enzyme preference in the search as a second measure of data quality. After searching 
data against our synthetic database, our confidence in bona fide phosphopeptide identification 
and site localization was increased to only include true hits (0%FDR) and required 
phosphopeptides to have an Ascore greater than or equal to a value that confers 99% site 
localization [37]. As a result, we confidently identified phosphorylation at serine-38, serine-62, 
serine-73, serine-298, serine-302, serine-496 and serine-571 of FLCN (Figure 6b). No threonine 
or tyrosine phosphorylation sites were identified using our experimental conditions, although 
they were allowed as variable modifications in all data searches using the SEQUEST algorithm.  
To understand FLCN phosphorylation in a quantitative manner, we used a chemical labelling 
strategy to compare untreated samples to conditions of pharmacological inhibition.  To perform 
such a strategy, following tryptic digestion of FLCN from each experimental condition, an equal 
amount of peptides were labelled through a reductive amination reaction, which adds a dimethyl 
group to peptide N-termini and C-terminal lysine residues. Untreated FLCN was labelled with 
isotopically pure dimethyl groups containing 
1
H, while all experimental conditions were labelled 
to contain isotopically pure deuterium (
2
H). Labelled peptides from each condition were 
separately combined with labelled peptides from the untreated control condition at a ratio of 1:1 
(wt/wt). Chemical labelling allowed for peptides to be quantified based the induced mass 
difference so distinct m/z states could be resolved by mass spectrometry and not effect peptide 
elution from liquid chromatography as 
2
H and 
1
H species share the same structure. We were able 
to readily identify and quantify phosphorylated FLCN with this workflow, yet large standard 
deviations did not permit any great biological elucidation even following a normalization to the 
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non-phosphorylated, quantified FLCN peptides (Supplemental Figure S2, Supplemental Table 
S8).  
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Figure 7. Gene Ontology enrichment identifies FLCN to have roles in transport and 
translation A) Enriched biological processes are given as a function of p-value generated by 
uploading the full list of FLCN binding proteins to the DAVID bioinformatics portal in the IPI 
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format (http://david.abcc.ncifcrf.gov/). The top twenty-four GO biological process terms are 
provided. The full gene list for each term can be found in Supplemental Table S4. B) Enriched 
functional protein domains from FLCN binding partners were identified using the DAVID 
bioinformatics portal and INTERPRO domain annotation. The top twenty-two identifications are 
provided and the full list of gene names can be found in Supplemental Table S5.  
 
 Of the phosphorylation sites identified, serine-38, serine-62 and serine-571 were found to 
the greatest extent and to the greatest stoichiometry across conditions in both quantitative and 
binary analyses (Supplemental Table S2, S3). Interestingly, LY294002 treatment induced 
phosphorylation at serine-496 which was not identified under other conditions, suggesting the 
possibility of PI3K-regulated changes in FLCN modification. Although this remains a binary 
comparison, outside of this site pharmacological inhibition by other drugs did not produce 
significant changes in phosphorylated amino acids. This comes as a surprise as previous work 
has identified the TSC2-mTOR pathway to regulate FLCN phosphorylation at serine-62 and 
serine-302 in HeLa, HEK293 and Cos2 cells through over-expression studies [26]. While robust 
changes in FLCN phosphorylation—as detected by site-specific antibodies and inferred through 
mobility shift upon protein separation by SDS-PAGE—were seen, the results could not be 
recapitulated in our hands under a more advanced proteomic approach. It is possible to mitigate 
disparate findings by comparing the concentration of inhibitor used; however, a more likely 
interpretation is that multiple kinases phosphorylate FLCN, and over-expression or robust 
depletion of specific kinases is required.  
 The majority of FLCN phosphorylation sites were found to be proline-directed; 
phosphorylated serine residues in FLCN are followed at the +1 position by a proline residue. 
While not entirely reductive, this finding rules out the specificity of several kinases and kinase 
families. Indeed from structural studies, we know that basophilic kinases, such as PKA, PKG and 
PKC (AGC kinases), calmodulin-dependent protein kinases (CAMK kinases) and the majority of 
serine/threonine kinases and phosphatases heavily disfavour proline at the P+1 position [51, 52]. 
On the other hand, cyclin-dependent protein kinases (CDKs) and mitogen-activated protein 
kinases (MAPKs) are both proline-directed, which suggests FLCN may be induced by cell-cycle 
dependent mechanisms. Indeed CDK2 was identified in our screen and other kinases such as 
polo-like kinases and aurora kinases are likely modifiers of FLCN. This hypothesis is supported 
by the identification of aurora kinase A (AURKA) in our proteomic screen, and the fact that 
polo-like domains readily bind pS-P-X motifs (Supplemental Table S5) [53]. Interestingly, all of 
36 
 
the kinases suggested thus far regulate some aspect of commitment to cell cycle or its subsequent 
regulation.  
To analyse the phosphorylation state of FLCN and its known, functional complex further, 
we performed assays to enrich for FNIP1, FNIP2 and a regulator of mTORC1 signalling, TIP41. 
We identified 5 novel phosphorylation sites on FNIP1, 8 novel phosphorylation sites of FNIP2 
and 3 novel phosphorylation sites on TIP41 (Supplemental Figure S4). To study FNIP1 
phosphorylation we co-transfected either full-length ULK1 or ULK1
K48I
. We identified 9 total 
phosphorylation sites on FNIP1 and just over half of the sites identified were found upon co-
transfection with wild-type ULK1. In terms of phosphorylation site location on FNIP1, the sites 
identified are found throughout the full length of the relatively large protein and interacting 
domain with FLCN. With regards to FNIP2, we identified a total of 15 phosphorylation sites by 
either transfecting cells with FNIP2 alone, or co-transfecting with ULK1. Interestingly, more 
FNIP2 phosphorylation sites were identified without co-transfection of ULK1. All sites 
identified by co-transfection with ULK1 were also identified in FNIP2 alone, suggesting that 
ULK1 does not phosphorylate FNIP2, or, overexpression of ULK1 actually negatively regulates 
FNIP2 phosphorylation. We also identified phosphorylation sites in the AMPK-binding domain 
of FNIP2. TIP41 phosphorylation, a regulator of the PP2a phosphatase, and subsequent regulator 
of mTORC1 signalling, was also examined by incubating cells with insulin alone, or with insulin 
and rapamycin. Only three phosphorylation sites were identified on TIP41, however, none of 
these sites have been annotated in either Uniprot or the Phosphosite repositories for post-
translational modification data. One unique phosphorylation site on TIP41 was found in each 
experimental condition (Supplemental Table S10, Supplemental Figure 4). 
3.9 FLCN-interactome related to disease progression and common disease phenotypes 
The list of FLCN binding partners was manually interrogated to examine possible interactions, 
which may play a role in the disease progression of BHD, or, already have a known pathological 
function. We wanted to determine if these potential FLCN interactions could be validated. 
Therefore, we employed an immuno-affinity enrichment endogenous FLCN from HEK293 cells, 
and blotted with antibodies against several identified proteins including SUZ12, TAB1, TAK1, 
ULK1, CAD, mTOR and FASN (Figure 8). Several proteins, including FASN and CAD, 
although identified by mass spectrometry with a high number of spectra are possible 
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contaminating proteins, and GST binding alone could not be ruled out. Therefore, outside of 
SUZ12, data from endogenous immunoprecipitations is omitted for this manuscript.  
While CAD may in fact be a contaminant, as many repeated attempts to validate its 
endogenous interaction with FLCN by pull-down have yielded few positive results, its validation 
as a FLCN binding partner holds much promise and much interest from previous work in the 
field. Through personal communication a collaborator,  Lisa Henske (Harvard Medical School, 
Boston), evidence from lower organisms is mounting to support a bona fide interaction between 
FLCN and CAD. CAD is essential for de novo pyrimidine biosynthesis and acts as a fusion of 
four catalytic activities, underlying the rate limiting steps of the anabolic process, and further, its 
activity is regulated by mTORC1 signalling and is directly phosphorylated at serine-1859 by 
S6K1. This phosphorylation event specifically enhances the E3 activity of CAD in vivo to 
synthesize new pyrimidine nucleotides [54]. Further, CAD has also been identified as a binding 
partner of Rheb, the small G protein that inhibits mTOR, in a GTP-dependent manner. GTP-
Rheb over-expression localizes CAD to lysosomes, suggesting a role for pyrimidine biosynthesis 
or inhibition through localization. The implication of Rheb involvement and its true validation as 
a binding partner remains somewhat myopic as all studies were performed by over-expression 
[55]. Our identification of mTOR by mass spectrometry (yet to be validated endogenously) 
complicates this story even further (Supplemental Table S5).  
It is equally exciting, paradoxical, and mechanistically frustrating that FLCN is found 
throughout mTOR related signalling pathways yet we cannot readily say where in the pathway it 
functions. If FLCN truly binds CAD—as it does so many other proteins—it should be 
hypothesized that FLCN may play a greater role in localization and complex formation rather 
than any one unique catalytic activity. Indeed, due to the discovery of so many interacting 
proteins, we may want to compare similarities between several functionally distinct FLCN 
targets in parallel to gain insight into its function. The most readily accessible way to direct this 
comparison would not be based on crystallographic or a priori structural knowledge alone. 
Already the list of validated FLCN targets suggests many distinct binding modalities, some of 
which are likely facilitated by FNIP1 and FNIP2. Further, we know from structural and sequence 
information that distinct protein:protein interactions rarely if ever occur through competition for 
exactly the same amino acid sequence. Therefore perhaps the best way to assess the molecular 
function of FLCN is by comparing its interaction with a single type of enzyme in two distinct, 
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well-established signalling pathways. With this assertion, the serine/threonine protein kinase 
TAK1 (MAP3K7), which plays a role in innate immune signalling through TRAF6—also an 
ULK1 modifying E3 ubiquitin ligase—and TGF-beta signalling, could readily be compared to 
another kinase identified in our screen, Aurora Kinase A (AURKA). Examining the same class 
of enzyme streamlines to a shared functional readout so comparisons can be drawn by kinase 
assay. Further as AURKA functions in the nucleus and TAK1 has no acknowledged nuclear 
function, these targets could be used to examine how FLCN mutational status dictates protein 
localization and function [56].  
 
3.10 FLCN as a regulator of biology in the nucleus and primary cilia 
Of further interest and intellectual complexity, SUZ12, a key component of the polycomb 
repressive complex, which silences gene expression through histone methylation, was validated 
as an endogenous interacting partner of FLCN (Figure 8a). Loss of the polycomb repressive 
complex including SUZ12 has been shown to amplify RAS signalling in cancer [57]. 
Furthermore, SUZ12 mutation has been found as a common mutation in peripheral nerve sheath 
tumours in a related tumour syndrome, neurofibromatosis type 1 (NF1) [58, 59].  Outside of our 
novel finding of SUZ12 direct binding to FLCN, no data has connected SUZ12 to BHD 
Syndrome and the molecular consequence of this interaction remains unknown, although it is 
likely to affect cell differentiation as Suz12
-/-
 embryonic stem cells are unable to undergo proper 
differentiation [60]. With regard to transcriptional regulation and genome integrity, we further 
identified DNA-PKc, a kinase that acts as a sensor for DNA damage, as a FLCN binding partner 
(Figure 8b). These endogenous validations open a completely novel avenue of BHD and FLCN-
related research towards understanding genomic anomalies propagated in the disease state. 
 Somewhat distinct from its acknowledged proclivity for neoplastic induction, BHD has 
recently been shown to act as a ciliopathy; a disease propagated by dysfunctional primary cilia. 
We wanted to further understand and examine cilia signalling components by assessing 
temporally-dependent changes following gene knockdown [34]. Upon a close inspection of our 
proteomic investigation, we identified a significant number of cilia-specific or cilia-related 
protein components. For example, FLCN was found to bind components of the CCT/TRiC 
family of chaperones which mediate BBSome assembly and primary cilia formation [61]. FLCN 
was also found to bind Aurora kinase A (AURKA) which regulates primary cilia stability 
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through the phosphoinositide signalling of inositol polyphosphate 5-phosphatase E (INPP5E), 
and further, disassembly through a calmodulin-dependent mechanism (Supplemental Table S5) 
[62, 63]. Additionally, we identified a number of proteasomal proteins as FLCN binding 
partners, which is particularly exciting, as recent evidence has demonstrated an essential role for 
the proteasome in the formation and extension of the primary cilia axoneme. Significant cross-
talk between the primary cilia, the proteasome and autophagy—all biological realms that FLCN 
has been suspected to act upon—are areas which require further attention for a better 
understanding of ciliopathies [64-66]. 
FLCN was also identified to bind a number of components of the nucleopore complex, 
yet few of these proteins have been identified to localize to the primary cilia transition zone, a 
secondary site of nucleopore protein action [67]. The identification of NUP50, NUP53, NUP54, 
NUP133, NUP150, NUP153, NUP155, NUP160, NUP188 and NUP205 suggests that FLCN has 
some largely unknown role at the nucleopore (Supplemental Table S3). Since FLCN has been 
shown to act on the small G-protein complex Rag-C/D to participate in mTOR signaling, it is not 
unlikely that FLCN could bind and regulate additional small G proteins such as Ran, a critical 
mediator of trafficking to the nucleus and primary cilia. This binding event could regulate FLCN 
to a greater extent than Ran, and dictate the localization and binding capacity of FLCN as well. 
With supporting evidence from our lab and others, it is hypothesized that FLCN may provide a 
Ran-directed trafficking function through direct binding and post-translational modification 
status. Indeed, FLCN shares some homology to DENN domain containing proteins which 
regulate Rab small GTPases. However FLCN likely employs a slightly different mechanism as it 
is missing the conserved consensus FCFP motif in uDENN domains and widely conserved 
SxLxPxFxxxxxxL motif in DENN domains (Supplemental Figure S3) [68]. 
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Figure 8. Validation of novel endogenous FLCN interactions and relationship to Birt Hogg 
Dubé Syndrome disease progression 
A) FLCN was purified by immunoprecipitation and controlled for by incubating lysate with 
protein-G sepharose in the absence of anti-FLCN primary antibody. FLCN binding proteins were 
probed for with antibodies against SUZ12 and DNA-PKc. B) GST-FLCN was expressed in 
HEK293 cells and GST purified to identify co-immunoprecipitating proteins. DNA-pkc was 
probed for by Western blot in cells with or without GST-FLCN. Total DNA-pkc levels from 
whole cell lysate are shown as a control. C) UOK257 cells were infected with lentivirus 
containing shRNA against FLCN. Cells were passaged for 15  times or 170 times and compared 
to young progenitor cells. FLCN interacting proteins and proteins involved in signalling at the 
cilia were probed for by Western blot.  
 
   
With further regard to FLCN as the etiological agent of BHD, it was hypothesized that 
interacting partners and key pathways activating transcription, such as the NF-κB signalling 
Passage number 
 
Protein-G  
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IP: endogenous  
FLCN 
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pathway, may demonstrate protein level changes that correspond to disease progression. The NF-
κB signalling pathway was chosen for closer examination for several reasons. First, gene-
expression studies in embryonic stem cell and patient derived UOK257 cell-lines, with known 
FLCN mutations, showed a down-regulation of signalling components which are 
transcriptionally regulated by NF-κB, including TGFβ-RII [69].  Secondly, proteasomal 
function—a requirement for NF-κB signalling whose p105 precursor is processed to a smaller 
active p50 protein (NF-κBp50) by the 26S proteasome—was shown to be significantly 
dysregulated in a related ciliopathy, Bardet-Beidl Syndrome (BBS). Specifically in Bardet-Beidl 
Syndrome, the physical binding of the mutant etiological agents—the BBS family of proteins—
to core proteasome subunits impaired proteosomal function in the disease state [65, 70]. Lastly, 
NF-κB signalling is constitutively activated in a number of cancers including renal cell 
carcinoma [71, 72]. Exploiting proteasomal dysregulation could be favourable in a therapeutic 
setting in combination with mTORC1 inhibitors as previous work suggests that alterations to 
proteasome function are a central characteristic of ciliopathies. Therefore, to resolve the function 
of NF-κB in BHD, work comparing the levels of the proteasomally processed NF-κB product, 
p105/p50, and other signalling proteins in tissues affected by BHD, or, in a model of BHD 
disease progression is critical to determine if known ciliopathies truly share this mechanistic 
commonality.  
Without access to human tissue, we began assessing the NF-κB pathway and proteasome 
function in a model developed in human cortical renal tubule cells to recapitulate disease 
progression. We utilized cells at passage 15 and passage 170, with a stable, lentiviral knockdown 
of FLCN as “new” and “old” cells, respectively, and we began our investigation by western 
blotting for the protein p65/RelA, a central component of the NF-κB pathway. Canonically, RelA 
forms a dimer with NF-κBp50 following proteasomal processing of p105 and several 
phosphorylation events [70]. To act as a transcription-activating complex, RelA-p50 requires 
stable disassociation from an inhibitory protein, Inhibitor of kappa-B (IκBα). The inhibitory 
protein, IκBα, masks the nuclear localization signal of NF-κB and sequesters the inactive 
transcription factor in the cytoplasm. The RelA-p50 complex is released from inhibition by the 
IκB kinase complex, IKK, composed of α and β catalytic subunits and a regulatory γ subunit. 
Phosphorylation of IκBα at serine-32 and serine-36 leads to dissociation and proteasomal 
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degradation of IκBα, allowing the active RelA-p50  dimer can enter the nucleus and function as a 
transcriptional activator [73, 74].  
By immunoblotting for RelA, we identified no significant change in its phosphorylation 
at serine-536 nor protein level abundance, relative to a tubulin control, and conclude that RelA 
status alone is not affected by loss of FLCN. However, we detected small but significant protein 
level changes in IKKα, the core catalytic component of the heterotrimeric IκB complex (Figure 
8C). IKKα appears to be upregulated in late-passaged, FLCN depleted cells, relative to lower-
passaged cells with and without FLCN expression. This comes as somewhat of a surprise as 
upstream IKKα would likely affect the protein levels and phosphorylation status of RelA. 
However, a further analysis of IκBα and NF-κBp50 levels and phosphorylation status is required 
to conclusively determine how the NF-κB may be dysregulated in BHD. Additionally, treatment 
with Velcade/bortezomib (PS-341), a potent inhibitor of the 26S proteasome, could be useful as a 
tool to understanding this pathway.  
To examine possible alterations in transcription as a function of FLCN status, we used 
luciferase assays to experimentally determine the output of NF-κB signalling and TGF-beta 
signalling. HK2 cells depleted of endogenous FLCN were transfected transiently with pcDNA3 
or cDNA to HA-FLCN, HA-FLCN
K508R
, HA-FLCN
Y463X
, or HA-FLCN
H42G
. Mutant variants of 
FLCN were chosen as they are seen in cases of clear cell renal cell carcinoma (CCRCC) or are 
known to significantly abrogate signalling through FLCN [75]. We hypothesized that mutations 
in FLCN leading to loss of function would have a significant effect on the transcription of TGF-
beta or NF-κB regulated genes. To assess the role of FLCN on NF-κB and TGF-beta signalling, 
we co-transfected HK2 cells with luciferase reporter constructs to either NF-κB or SMAD, 
controlled for by renilla-luciferase. The SBE4-reporter construct, containing four SMAD 
response elements was used to examine TGF-β signalling and a separate NF-κB construct was 
used as a distinct readout. Following transfection, cells were provided fresh media and the NF-
κB pathway was induced through the addition of TGF-β to a final concentration of 100ng/mL. 
The induction of this pathway was controlled for experimentally by treating half of the renilla-
controlled and NF-κB reporter transfected cells with ddH2O. To assess reporter intensity in a 
quantitative, statistically controlled manner, each experimental and control condition was 
repeated in triplicate (Supplemental Figure S2). In addition to HA-tagged FLCN constructs, we 
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attempted to use GFP-FLCN
S62A
, GFP-FLCN
S62D
, and GFP-FLCN
S62E 
constructs (data not 
shown).  
We next sought to determine if we could identify signalling proteins with known roles at 
primary cilia to further support BHD as a true ciliopathy. Interestingly, Birt-Hogg-Dubé 
syndrome’s role as a ciliopathy also ties into its known metabolic abnormalities. Cellular 
machinery involved in ciliogenesis participates in autophagy and blocking autophagy enhances 
primary cilia grown and associated signalling [76]. We examined the β-catenin protein as the 
Wnt and β-catenin signalling pathway is regulated by cilia. While the exact mechanism remains 
incomplete, it appears that functional cilia negatively regulate β-catenin levels. Indeed, in 
Bardet-Biedl syndrome, there is an accumulation of β-catenin as a result of deficient cilia [77]. 
To support the role of FLCN loss in promoting changes in cilia, we identified a significant 
increase in β-catenin levels in late passaged cells (Figure 8c). This suggests a significant 
dysregulation in cilia, similar to that seen in BBS. Further, this finding supports the previous 
finding that identified activation of canonical WNT signalling following FLCN knockdown [34]. 
Constitutive activation of WNT signalling upon FLCN loss would ultimately promote 
developmentally regulated transcriptional programs and progression to a neoplastic state. 
Additional work is needed to characterize Hedgehog signalling in BHD and FLCN-null cells, as 
it remains the most well characterized pathway linking primary cilia to developmentally 
regulated processes [78-80]. Hedgehog signalling dysregulation has been identified in related 
ciliopathies, but remains a point of novelty in BHD.  
Outside of the primary cilium, we also examined protein level changes in the FLCN 
binding partner and chromatin remodelling protein, SUZ12. Of interest, SUZ12 levels increased 
upon the sustained loss of FLCN (Figure 8c). Due to the fact that SUZ12 acts as a transcriptional 
regulator, SUZ12 may act as a tumour suppressor to selectively repress particular genes, or, its 
accumulation could help further the transformation of FLCN-deficient cells. The genomic 
instability propagated by FLCN loss may be directly tied to chromatin remodelling proteins like 
SUZ12 and requires further study. Ideally, by looking at transcription-level data, or by inducing 
a secondary deficiency in SUZ12, we can further determine the effect this result has on disease 
progression and cellular transformation. 
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4. Discussion 
Here we identified novel protein interactions of the protein kinase, ULK1, and the metabolic 
tumour suppressor, FLCN. With regards to ULK1 many of these newly identified interactions 
suggest ULK1 to play a broader role outside of its known canonical contribution to autophagy. 
Indeed, ULK1 binding to another serine/threonine kinase, RSK4, suggests that ULK1 is able to 
mediate effects on other signalling pathways, or amplify its actions through further kinase 
recruitment. Additionally, integrating kinase signalling with vesicle formation dynamics remains 
a point of critical interest for further study. What signals are critically required for the formation 
and maturity of an autophagosome? And, how many signals are needed for short temporal 
responses in an energy-limited state? As studying these types of interactions are critical as novel 
findings in their own right, probing the functional role of ULK1 binding to targets with known 
roles in vesicle trafficking and formation, such as PIKfyve, will be essential to understand how 
the kinase dictates the autophagic status of the cell directly. Does ULK1 phosphorylate PIKfyve 
or the PIKfyve complex directly to alter phospholipid production, analogous to its role in 
Beclin1 and VPS34 complex regulation? Furthermore, does ULK1 regulation of PIKfyve act as a 
feedback mechanism to reduce PtdIns(3)P levels and stop autophagy? And, does the creation of 
PIKfyve products recruit a functionally distinct set of proteins to act at the nascent 
autophagosome? As a future direction, we will need to determine if ULK1 can directly 
phosphorylate PIKfyve, and if true, whether this modification alters the lipid kinase activity of 
PIKfyve. Further, now that we have established a phosphoproteomic workflow for identifying 
ULK1 substrates, continuing to employ this established protocol to identify more 
phosphorylation sites could identify PIKfyve as a regulated target.  
Outside of the canonical autophagy interacting network proposed by Chris Behrends and 
colleagues in 2010, we also identified a connection between ULK1 and ciliogenesis. Our 
discovery of an ULK1 interaction with ASAP1, and identification of endosomal proteins, 
warrants further experimental validation and insight as energy state, cell growth, autophagy and 
cell cycle progression are all linked to primary cilia [76]. The direct control of initiating events in 
ciliogenesis by a proposed ULK1-mediated mechanism could offer additional mechanistic 
explanation for cellular quiescence brought about under autophagic conditions. ULK1 
phosphorylation of ASAP1 could result in changes in Arf nucleotide binding and vesicle 
formation. Indeed, using the ULK1-inhibitor QG000052, which we were the first to validate as a 
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potent ULK1 kinase inhibitor over a very short time course, will be useful for understanding this 
mechanism. Because ciliogenesis and cilia extension and retraction is highly dynamic, a potent 
inhibitor like the one validated here could be used for live cell imagining of cilia where 
traditional genetic approaches would fall short.  
To further understand ULK1-interacting partners and whether they truly participate in 
autophagy, RNAi experiments to knock down binding partners should be carried out. The hope 
in doing this experiment would be to phenocopy the results that arise from inhibition of ULK1 in 
cells, or, some aspect of the autophagic process. It is highly unlikely that depletion of ASAP1, 
for example, would exactly replicate ULK1 loss; however, if they are true binding partners some 
functional arm of this axis will be lost.  
A finding from this study that warrants additional attention comes from our comparison 
of yeast Atg1 phosphorylation sites to their human counterparts. Under this analysis we begin to 
understand how a conserved pathway or functional system may evolve to support critical 
functions. Comparing the kinase-substrate library and targets of atg1 to human orthologues 
provides a somewhat contrary and distorted view on how autophagic machinery is canonically 
viewed. Although functional orthologues are widely noted, few identified phosphorylation sites 
share a high degree of identity. Indeed, due to this discovery that exceedingly few sites identified 
in this study are evolutionarily conserved, we must consider that higher metazoan autophagy—or 
at least processes directed by ULK1—may have evolved distinct roles to support an immune 
system and the period of starvation immediately following birth. While the autophagy-
interactome may be similar in total, its actual dynamics may be quite different as dictated by 
post-translational modifications. Indeed, we would expect multicellular organisms to employ 
autophagic machinery in a distinct manner to unicellular eukaryotes, such as S. cerevisiae, as 
time spent in a fasting state is vastly increased and requires higher-level input and hormonal 
cues. Therefore, while it is entirely appropriate to suggest evolutionarily conserved protein 
elements in the autophagy interaction network, it is incongruous to extrapolate post-translational 
modification data generated in lower orgasms to imply direct orthologous function and 
mechanism in humans. Requirements dictated through evolutionary pressure and time have 
likely created numerous distinct roles to support multicellular life and tissue-specific functions 
are confounded in the existing complexity of macroautophagy. The evolved complexity in 
macroautophagy, and other signalling systems, should be thought of under the lens of a model of 
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best fit, in which existing proteins are repurposed or given expanded function through changes in 
their degrees of freedom to subsequently the interaction network. An interesting preliminary 
investigation into this line of inquiry could be to consider potential differences arising from a 
quantitative phosphoproteomic screen against the same conserved kinase in different model 
organisms with a highly potent and selective inhibitor. This could answer if the same quantitative 
and site-specific differences arise across evolution, and, how conserved the autophagy-specific 
phosphoproteome is across species. While this study would be a fairly major undertaking it 
would elucidate sub-networks which arise as a consequence of evolution in a specific biological 
process. 
If we take a step back and consider ULK family kinase function alone, it appears to have 
necessary intrinsic, exogenous stress-induced actions similar to innate immune signalling 
whereby function—while pleiotropic—is only realized upon physiological barriers. Put simply, it 
is only through barriers and stressors to homeostasis do we likely realize some functionality. 
While ULK1 and ULK2 knockout studies have established a functional significance of 
autophagy in development, a second question remains: would endogenous over-expression of 
ULK1 or ULK2 result in altered primary metabolism, increased neoplastic potential, or altered 
immune functions?  
With regards to the tumour suppressor FLCN, we discovered a number of proteins and 
biological processes which the metabolic tumour suppressor is likely to regulate through direct 
interaction. Through bioinformatics, we also identified proteins domains in FLCN binding 
proteins which suggest further functional roles. The greatest up-regulated biological processes 
and domains were translation, cell cycle, regulation of protein ubiquitination, as well as HEAT 
and nucleotide binding domains. While the exact mechanism of many of these interactions 
remains somewhat nebulous, the identification of a number of proteins in mTORC1 signalling 
further solidifies its role as a metabolic tumour suppressor and regulator of this signalling 
pathway. Due to the fact that endogenous purification of FLCN and interacting proteins has 
remained a difficult task, using over-expression studies to validate some of these interactions will 
prove crucial. Moreover, as we identified protein level changes in some FLCN interactions, it 
would be interesting to extend this finding and probe for mTORC1 signalling components. Is the 
stoichiometry or localization of mTORC1 components significantly altered or directly influenced 
by FLCN loss?  
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By confirming direct interaction with several proteins that regulate transcription and 
genomic integrity, SUZ12 and DNA-PKc, we found further future directions to study FLCN as 
the etiological agent in Birt-Hogg-Dubé syndrome. These identifications support the 
acknowledged role of FLCN as a metabolic tumour suppressor involved in DNA damage repair; 
yet, they also put forth more nuanced roles for the protein with both cytoplasmic and nuclear 
functions. While not covered in this study, work from our lab has built upon these original 
interactions to demonstrate that functional loss of FLCN significantly affects genomic integrity 
as measured by an assay to detect telomere length as well as increased accumulation of DNA 
damage as FLCN-deficient cells are grown in continuous culture (as observed by γ-Histone 2AX 
phosphorylation). Knockdown of FLCN recapitulated our hypothesis and supported interactions. 
To further support this work we identified that several FLCN binding proteins change in a cell 
culture based model of BHD syndrome over time. Oddly, a number of FLCN binding protein 
accumulate systemically in response to FLCN loss which underlying various discrete signalling 
systems. Supporting previous work from other labs, we found that primary cilia proteins appear 
to be dysregulated and β-catenin is significantly up-regulated in old HK2 cells depleted of FLCN 
relative to lower passage counterparts.  
It is yet to be determined if BHD is truly similar to other ciliopathies with regards to 
altered proteasomal function, however the accumulation of these proteins is fairly suggestive. 
Further work will need to be done to determine if BHD functions in a manner similar to Bardet-
Beidl syndrome, where proteasomal function is blunted, and to determine which specific cilia 
receptors and signalling pathways are down-regulated by loss of FLCN. Support for this 
mechanism will provide additional therapeutic opportunities for treating BHD, as proteasomal 
inhibitors can be tested in preclinical models. 
Although we identified protein level changes in FLCN binding proteins to support and 
expand the classification of the syndrome as a ciliopathy, we also found changes that highlight 
significant, novel avenues of research. Indeed, the identification of a number of nucleopore 
proteins supports a role of FLCN in protein trafficking into the nucleus. We identified the 
NUP50, NUP53, NUP54, NUP133, NUP150, NUP153, NUP155, NUP160, NUP188 and 
NUP205 as binding partners of FLCN. These proteins are found at different areas in the 
nucleopore complex architecture, and some are located at the cytoplasmic, core, and nuclear 
sides of the complex. This proteomic finding, along with bioinformatics evidence suggests that 
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FLCN is highly tied to the nucleopore and likely has some trafficking function which is yet to be 
resolved. Current work by our lab and others suggests temporal localization and direct binding of 
FLCN with the nucleopore complex, and continued research to investigate this functional 
interaction will explain how FLCN and its loss may affect nuclear biology. More work needs to 
be done to assess which nucleopore proteins, and at what affinity FLCN is seen to be a binding 
direct partner. This will require further biochemical or in vitro approaches and pull-down 
strategies. Additionally, biophysical approaches like Biacore reaction could be used here. 
Overall, further interrogation of our proteomic datasets and their integration with this 
model of disease progression will be critical to understanding how loss of FLCN can lead to 
renal cancer development. It will be interesting to see if any interactions could potentiate novel 
treatment options, or, the repurposing of existing treatments for BHD and related ciliopathies. As 
we come to understand this set of rare diseases to a greater extent there is a significant hope to 
find commonalties to exploit. Indeed with this being said, a continuation of research into FLCN 
biology could go any number of directions. The most logical future progression of this research 
would be to determine if proteasome function is altered and if FLCN specifically binds to one or 
many small GTPases in a nucleotide-specific fashion. Moreover, due to the fact that FNIP1 and 
FNIP2 were only identified as minor binding partners, it may be valuable to perform 
immunoaffinity enrichments with these proteins and identify their unique functional interactions, 
if any truly exist. While out of the scope of this work, these novel future studies would also 
identify and support existing knowledge into FLCN interactions and elucidate core FLCN-
FNIP1-FNIP2 complexes.  
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5. Summary of research highlights 
1) Characterisation of a novel ULK1 inhibitor—a limitation in the autophagy field has been 
a lack of a drug inhibitor of ULK1 and initiating kinases. Consequently, this new drug, 
QG000052, will be of considerable interest to the autophagy community. The validation of its 
specificity and temporal response is further support for its use in other models.  
 
 
 
 
 
 
2) Identification of new ULK1 
protein interactions involved in 
fundamental processes of autophagy 
including PIKfyve/Vac14, which is 
critically involved in autosomal 
maturation from the ER and subequent 
translocation to the lysosome, support 
new avenues of research and a better 
understanding of the complex, dynamic 
biological process.  
 
3) Identification of disparity 
between human ULK1 and S. cerevisiae 
atg1 targets highlights distinct and 
shared targets, and further support to 
study autophagy to a greater extent in 
human cell lines.  
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Supplemental Figure S1. Quantification of chemically labelled, phosphorylated FLCN 
peptides under pharmacological inhibitor treatment. 
A)To determine how cell treatments effected FLCN phosphorylation status chemically labeled 
peptides were combined so the ratio of treated:untreated samples was 1:1 (wt/wt). HK2 cells 
over-expressing FLCN were treated with B) insulin, C) insulin and rapamycin, D) insulin and 
LY294002, E) 2-deoxy-glucose, or, F) 2-deoxy-glucose and compound C and quantitatively 
compared to an untreated control condition. High-resolution quantitative mass spectrometry was 
used to resolve the mass difference between treated and untreated peptides and quantification 
was performed by comparing the relative difference in abundance of isotopically-labelled heavy 
and light precursor masses. The identified phosphorylation site number, treatment, and 
identification statistics are provided. The full list of FLCN phosphorylation sites from this 
experiment can be found in Supplemental Table S8. 
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Supplemental Figure S2. Luciferase assay measurements to detect the role of FLCN 
mutation in NF-κB and TGF- β signalling response.  
HK2 cells depleted of endogenous FLCN were transfected transiently with cDNA to pCDNA3, 
HA-FLCN, HA-FLCNK
508R
, HA-FLCN
Y463X
, or HA-FLCN
H42G
 and either an NF-κB or SMAD 
reporter construct with a renilla control for transfection efficiency in a 96-well plate. Following 
transfection, cells were supplemented with 1ng/mL of TGF-β or mock treated with water. 
Fluorescence of reporter and transfection control constructs was visualized on a plate reader 6 
hours after stimulation.  
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Supplemental Figure S3. Multiple sequence alignment of FLCN and DEN1A and DEN1B 
highlights DENN-like domain in FLCN.  
Full length FLCN (Q8NFG4), DEN1A (Q8TEH3) and DEN1B (Q6P3S1) were analyzed for 
sequence similarity using the ClustalW2 multiple sequence alignment software 
(http://www.ebi.ac.uk/Tools/msa/clustalw2). Identity is denoted by (*) and similarity by (:) and 
(.).  
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Supplemental Figure S4. Identification of FNIP1, FNIP2 and TIP41 phosphorylation sites. 
A-C) Following pull-down of GST-FNIP1, GST-FNIP2 and GST-TIP41, bands corresponding to 
within a 10kDa window of each protein’s molecular weight was excised and processed for 
analysis by mass spectrometry. D-F) Phosphorylation sites from each protein and experimental 
condition were identified by high-resolution mass spectrometry. Unique phosphorylation sites 
that do not overlap between treatment and control conditions are provided in bold, and the gene, 
experimental treatment, total number of phosphopeptides identified and phosphorylation site 
number (uniprot numbering) are provided for each protein. 
